Cardiac plasticity

New England Journal of Medicine

Volumn 358, Issue 13, 2008, Pages 1370-

  Hill, Joseph A ^a,b   Olson, Eric N ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR RISK; DYNAMICS; HEART ARRHYTHMIA; HEART DEVELOPMENT; HEART DISEASE; HEART FAILURE; HEART HEMODYNAMICS; HEART HYPERTROPHY; HEART MUSCLE ATROPHY; HUMAN; MOLECULAR BIOLOGY; PATHOPHYSIOLOGY; PHENOTYPE; PLASTICITY; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; CARDIOMEGALY; CYTOLOGY; EXTRACELLULAR SPACE; GROWTH, DEVELOPMENT AND AGING; HEART; HEART MUSCLE; HEART MUSCLE CELL; HEART VENTRICLE REMODELING; PHYSIOLOGY;

CARDIOMEGALY; EXTRACELLULAR SPACE; HEART; HUMANS; MYOCARDIUM; MYOCYTES, CARDIAC; PHENOTYPE; SIGNAL TRANSDUCTION; VENTRICULAR REMODELING;

EID: 41449086790     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMra072139     Document Type: Review

References (127)

1. Frey N, Olson EN. Cardiac hypertrophy: the good, the bad, and the ugly. Annu Rev Physiol 2003;65:45-79.
2. Heineke J, Molkentin JD. Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat Rev Mol Cell Biol 2006;7:589-600.
3. Hilfiker-Kleiner D, Landmesser U, Drexler H. Molecular mechanisms in heart failure: focus on cardiac hypertrophy, inflammation, angiogenesis, and apoptosis. J Am Coll Cardiol 2006;48:Suppl A:56-66.
4. Razeghi P, Taegtmeyer H. Hypertrophy and atrophy of the heart: the other side of remodeling. Ann N Y Acad Sci 2006;1080:110-9.
5. Frey N, Katus HA, Olson EN, Hill JA. Hypertrophy of the heart: a new therapeutic target? Circulation 2004;109:1580-9.
6. Chien KR. Stress pathways and heart failure. Cell 1999;98:555-8.
7. Milliken MC, Stray-Gundersen J, Peshock RM, Katz J, Mitchell JH. Left ventricular mass as determined by magnetic resonance imaging in male endurance athletes. Am J Cardiol 1988;62:301-5.
8. Fagard R. Athlete's heart. Heart 2003;89:1455-61.
9. Rockman HA, Ross RS, Harris AN, et al. Segregation of atrial-specific and inducible expression of an atrial natriuretic factor transgene in an in vivo murine model of cardiac hypertrophy. Proc Natl Acad Sci U S A 1991;88:8277-81. [Erratum, Proc Natl Acad Sci U S A 1991;88:9907.]
10. Hill JA, Karimi M, Kutschke W, et al. Cardiac hypertrophy is not a required compensatory response to short-term pressure overload. Circulation 2000;101:2863-9.
11. Thompson PD. D. Bruce Dill Historical Lecture: historical concepts of the athlete's heart. Med Sci Sports Exerc 2004;36:363-70.
12. Bicycle heart. Br Med J 1898;1:908.
13. Osler W. The principles and practice of medicine. New York: Appleton, 1892.
14. Sandler H, Dodge HT. Left ventricular tension and stress in man. Circ Res 1963;13:91-104.
15. Hood WP Jr, Rackley CE, Rolett EL. Wall stress in the normal and hypertrophied human left ventricle. Am J Cardiol 1968;22:550-8.
16. Grossman W, Jones D, McLaurin LP. Wall stress and patterns of hypertrophy in the human left ventricle. J Clin Invest 1975;56:56-64.
17. Meerson FZ. On the mechanism of compensatory hyperfunction and insufficiency of the heart. Cor Vasa 1961;3:161-77.
18. Gunther S, Grossman W. Determinants of ventricular function in pressure-overload hypertrophy in man. Circulation 1979;59:679-88.
19. Huber D, Grimm J, Koch R, Krayenbuehl HP. Determinants of ejection performance in aortic stenosis. Circulation 1981;64:126-34.
20. Krayenbuehl HP, Hess OM, Ritter M, Monrad ES, Hoppeler H. Left ventricular systolic function in aortic stenosis. Eur Heart J 1988;9:19-23.
21. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990;322:1561-6.
22. Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991;114:345-52.
23. Lorell BH, Carabello BA. Left ventricular hypertrophy: pathogenesis, detection, and prognosis. Circulation 2000;102:470-9.
24. Dorn GW II, Robbins J, Sugden PH. Phenotyping hypertrophy: eschew obfuscation. Circ Res 2003;92:1171-5.
25. Dorn GW II. The fuzzy logic of physiological cardiac hypertrophy. Hypertension 2007;49:962-70.
26. Ganau A, Devereux RB, Roman MJ, et al. Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension. J Am Coll Cardiol 1992;19:1550-8.
27. Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man: anatomic validation of the method. Circulation 1977;55:613-8.
28. Semelka RC, Tomei E, Wagner S, et al. Interstudy reproducibility of dimensional and functional measurements between cine magnetic resonance studies in the morphologically abnormal left ventricle. Am Heart J 1990;119:1367-73.
29. Bottini PB, Carr AA, Prisant LM, Flickinger FW, Allison JD, Gottdiener JS. Magnetic resonance imaging compared to echocardiography to assess left ventricular mass in the hypertensive patient. Am J Hypertens 1995;8:221-8.
30. Pelliccia A, Maron BJ, Spataro A, Proschan MA, Spirito P. The upper limit of physiological cardiac hypertrophy in highly trained elite athletes. N Engl J Med 1991;324:295-301.
31. Fagard R, Aubert A, Lysens R, Staessen J, Vanhees L, Amery A. Noninvasive assessment of seasonal variations in cardiac structure and function in cyclists. Circulation 1983;67:896-901.
32. Mesa A, Jessurun C, Hernandez A, et al. Left ventricular diastolic function in normal human pregnancy. Circulation 1999;99:511-7.
33. Andersen JB, Rourke BC, Caiozzo VJ, Bennett AF, Hicks JW. Physiology: postprandial cardiac hypertrophy in pythons. Nature 2005;434:37-8.
34. Imamura T, McDermott PJ, Kent RL, Nagatsu M, Cooper G IV, Carabello BA. Acute changes in myosin heavy chain synthesis rate in pressure versus volume overload. Circ Res 1994;75:418-25.
35. Shiojima I, Sato K, Izumiya Y, et al. Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. J Clin Invest 2005;115:2108-18.
36. Kinugawa K, Yonekura K, Ribeiro RCJ, et al. Regulation of thyroid hormone receptor isoforms in physiological and pathological cardiac hypertrophy. Circ Res 2001;89:591-8.
37. Scheuer J, Malhotra A, Hirsch C, Capasso J, Schaible TF. Physiological cardiac hypertrophy corrects protein abnormalities associated with pathologic hypertrophy in rats. J Clin Invest 1982;70:1300-5.
38. Nakao K, Minobe W, Roden R, Bristow MR, Leinwand LA. Myosin heavy chain gene expression in human heart failure. J Clin Invest 1997;100:2362-70.
39. Miyata S, Minobe W, Bristow MR, Leinwand LA. Myosin heavy chain isoform expression in the failing and nonfailing human heart. Circ Res 2000;86:386-90.
40. Diffee GM, Seversen EA, Stein TD, Johnson JA. Microarray expression analysis of effects of exercise training: increase in atrial MLC-1 in rat ventricles. Am J Physiol Heart Circ Physiol 2003;284:H830-H837.
41. Calderone A, Takahashi N, Izzo NJ Jr, Thaik CM, Colucci WS. Pressure- and volume-induced left ventricular hypertrophies are associated with distinct myocyte phenotypes and differential induction of peptide growth factor mRNAs. Circulation 1995;92:2385-90.
42. Perrino C, Naga Prasad SV, Mao L, et al. Intermittent pressure overload triggers hypertrophy-independent cardiac dysfunction and vascular rarefaction. J Clin Invest 2006;116:1547-60.
43. Stitt TN, Drujan D, Clarke BA, et al. The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Mol Cell 2004;14:395-403.
44. Sandri M, Sandri C, Gilbert A, et al. Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 2004;117:399-412.
45. Skurk C, Izumiya Y, Maatz H, et al. The FOXO3a transcription factor regulates cardiac myocyte size downstream of AKT signaling. J Biol Chem 2005;280:20814-23.
46. Ni YG, Berenji K, Wang N, et al. Foxo transcription factors blunt cardiac hypertrophy by inhibiting calcineurin signaling. Circulation 2006;114:1159-68.
47. Hill JA. Electrical remodeling in cardiac hypertrophy. Trends Cardiovasc Med 2003;13:316-22.
48. Tomaselli GF, Zipes DP. What causes sudden death in heart failure? Circ Res 2004;95:754-63.
49. Haunstetter A, Izumo S. Toward antiapoptosis as a new treatment modality. Circ Res 2000;86:371-6.
50. Hein S, Arnon E, Kostin S, et al. Progression from compensated hypertrophy to failure in the pressure-overloaded human heart: structural deterioration and compensatory mechanisms. Circulation 2003;107:984-91.
51. Spirito P, Maron BJ, Bonow RO, Epstein SE. Occurrence and significance of progressive left ventricular wall thinning and relative cavity dilatation in hypertrophic cardiomyopathy. Am J Cardiol 1987;60:123-9.
52. Gaasch WH, Zile MR, Hoshino PK, Apstein CS, Blaustein AS. Stress-shortening relations and myocardial blood-flow in compensated and failing canine hearts with pressure-overload hypertrophy. Circulation 1989;79:872-83.
53. Sano M, Minamino T, Toko H, et al. p53-Induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload. Nature 2007;446:444-8.
54. Weber KT. Extracellular matrix remodeling in heart failure: a role for de novo angiotensin II generation. Circulation 1997;96:4065-82.
55. Bristow MR. Why does the myocardium fail? Insights from basic science. Lancet 1998;352:Suppl 1:SI8-SI14.
56. Rockman HA, Koch WJ, Lefkowitz RJ. Seven-transmembrane-spanning receptors and heart function. Nature 2002;415:206-12.
57. Levine B, Klionsky DJ. Development by self-digestion: molecular mechanisms and biological functions of autophagy. Dev Cell 2004;6:463-77.
58. Lum JJ, DeBerardinis RJ, Thompson CB. Autophagy in metazoans: cell survival in the land of plenty. Nat Rev Mol Cell Biol 2005;6:439-48.
59. Matsui Y, Takagi H, Qu X, et al. Distinct roles of autophagy in the heart during ischemia and reperfusion: roles of AMP-activated protein kinase and Beclin 1 in mediating autophagy. Circ Res 2007;100:914-22.
60. Zhu H, Tannous P, Johnstone JL, et al. Cardiac autophagy is a maladaptive response to hemodynamic stress. J Clin Invest 2007;117:1782-93.
61. Nakai A, Yamaguchi O, Takeda T, et al. The role of autophagy in cardiomyocytes in the basal state and in response to hemodynamic stress. Nat Med 2007;13:619-24.
62. Rothermel BA, Hill JA. Myocyte autophagy in heart disease: friend or foe? Autophagy 2007;3:632-4.
63. Tannous P, Zhu H, Johnstone JL, et al. Intracellular protein aggregation is a proximal trigger of cardiomyocyte autophagy. Circulation (in press).
64. Perhonen MA, Franco F, Lane LD, et al. Cardiac atrophy after bed rest and space-flight. J Appl Physiol 2001;91:645-53.
65. de Groot PC, van Dijk A, van Dijk E, Hopman MT. Preserved cardiac function after chronic spinal cord injury. Arch Phys Med Rehabil 2006;87:1195-200.
66. Lisy O, Redfield MM, Schirger JA, Burnett JC Jr. Atrial BNP endocrine function during chronic unloading of the normal canine heart. Am J Physiol Regul Integr Comp Physiol 2005;288:R158-R162.
67. Krayenbuehl HP, Hess OM, Monrad ES, Schneider J, Mall G, Turina M. Left ventricular myocardial structure in aortic valve disease before, intermediate, and late after aortic valve replacement. Circulation 1989;79:744-55.
68. Villari B, Vassalli G, Monrad ES, Chiariello M, Turina M, Hess OM. Normalization of diastolic dysfunction in aortic stenosis late after valve replacement. Circulation 1995;91:2353-8.
69. Lecker SH, Goldberg AL, Mitch WE. Protein degradation by the ubiquitin-proteasome pathway in normal and disease states. J Am Soc Nephrol 2006;17:1807-19.
70. Bodine SC, Latres E, Baumhueter S, et al. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 2001;294:1704-8.
71. Glass DJ. Molecular mechanisms modulating muscle mass. Trends Mol Med 2003;9:344-50.
72. Lecker SH, Jagoe RT, Gilbert A, et al. Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression. FASEB J 2004;18:39-51.
73. Rothermel BA, McKinsey TA, Vega RB, et al. Myocyte-enriched calcineurin-interacting protein, MCIP1, inhibits cardiac hypertrophy in vivo. Proc Natl Acad Sci U S A 2001;98:3328-33.
74. Hill JA, Rothermel B, Yoo KD, et al. Targeted inhibition of calcineurin in pressure-overload cardiac hypertrophy: preservation of systolic function. J Biol Chem 2002;277:10251-5.
75. Olson EN, Backs J, McKinsey TA. Control of cardiac hypertrophy and heart failure by histone acetylation/deacetylation. Novartis Found Symp 2006;274:3-12.
76. Kerkelä R, Woulfe K, Force T. Glycogen synthase kinase-3beta - actively inhibiting hypertrophy. Trends Cardiovasc Med 2007;17:91-6.
77. Li HH, Kedar V, Zhang C, et al. Atrogin-1/muscle atrophy F-box inhibits calcineurin-dependent cardiac hypertrophy by participating in an SCF ubiquitin ligase complex. J Clin Invest 2004;114:1058-71.
78. Ago T, Sadoshima J. Thioredoxin1 as a negative regulator of cardiac hypertrophy. Antioxid Redox Signal 2007;9:679-87.
79. Hardt SE, Sadoshima J. Negative regulators of cardiac hypertrophy. Cardiovasc Res 2004;63:500-9.
80. Sadoshima J, Izumo S. The cellular and molecular response of cardiac myocytes to mechanical stress. Annu Rev Physiol 1997;59:551-71.
81. Serneri GGN, Modesti PA, Boddi M, et al. Cardiac growth factors in human hypertrophy: relations with myocardial contractility and wall stress. Circ Res 1999;85:57-67.
82. Zou Y, Akazawa H, Qin Y, et al. Mechanical stress activates angiotensin II type 1 receptor without the involvement of angiotensin II. Nat Cell Biol 2004;6:499-506.
83. Chien KR. Meeting Koch's postulates for calcium signaling in cardiac hypertrophy. J Clin Invest 2000;105:1339-42.
84. Ramirez MT, Zhao XL, Schulman H, Brown JH. The nuclear deltaB isoform of Ca2+/calmodulin-dependent protein kinase II regulates atrial natriuretic factor gene expression in ventricular myocytes. J Biol Chem 1997;272:31203-8.
85. Passier R, Zeng H, Frey N, et al. CaM kinase signaling induces cardiac hypertrophy and activates the MEF2 transcription factor in vivo. J Clin Invest 2000;105:1395-406.
86. Sugden PH. Signalling pathways in cardiac myocyte hypertrophy. Ann Med 2001;33:611-22.
87. Shiojima I, Walsh K. Regulation of cardiac growth and coronary angiogenesis by the Akt/PKB signaling pathway. Genes Dev 2006;20:3347-65.
88. Molkentin JD, Lu JR, Antos CL, et al. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 1998;93:215-28.
89. Wilkins BJ, Dai YS, Bueno OF, et al. Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy. Circ Res 2004;94:110-8.
90. Ritter O, Hack S, Schuh K, et al. Calcineurin in human heart hypertrophy. Circulation 2002;105:2265-9.
91. Lim HW, Molkentin JD. Calcineurin and human heart failure. Nat Med 1999;5:246-7.
92. Tsao L, Neville C, Musaro A, McCullagh KJ, Rosenthal N. Revisiting calcineurin and human heart failure. Nat Med 2000;6:2-3.
93. Haq S, Choukroun G, Lim H, et al. Differential activation of signal transduction pathways in human hearts with hypertrophy versus advanced heart failure. Circulation 2001;103:670-7.
94. Diedrichs H, Chi M, Boelck B, Mehlhorm U, Schwinger RH. Increased regulatory activity of the calcineurin/NFAT pathway in human heart failure. Eur J Heart Fail 2004;6:3-9. [Erratum, Eur J Heart Fail 2004;6:823.]
95. Chin ER, Olson EN, Richardson JA, et al. A calcineurin-dependent transcriptional pathway controls skeletal muscle fiber type. Genes Dev 1998;12:2499-509.
96. Naya FJ, Mercer B, Shelton J, Richardson JA, Williams RS, Olson EN. Stimulation of slow skeletal muscle fiber gene expression by calcineurin in vivo. J Biol Chem 2000;275:4545-8.
97. Potthoff MJ, Wu H, Arnold MA, et al. Histone deacetylase degradation and MEF2 activation promote the formation of slow-twitch myofibers. J Clin Invest 2007;117:2459-67.
98. Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK. The progression from hypertension to congestive heart failure. JAMA 1996;275:1557-62.
99. Frohlich ED, Apstein C, Chobanian AV, et al. The heart in hypertension. N Engl J Med 1992;327:998-1008. [Erratum, N Engl J Med 1992;327:1768.]
100. Schillaci G, Verdecchia P, Porcellati C, Cuccurullo O, Cosco C, Perticone F. Continuous relation between left ventricular mass and cardiovascular risk in essential hypertension. Hypertension 2000;35:580-6.
101. Verdecchia P, Carini G, Circo A, et al. Left ventricular mass and cardiovascular morbidity in essential hypertension: the MAVI study. J Am Coll Cardiol 2001;38:1829-35.
102. Verdecchia P, Schillaci G, Borgioni C, et al. Adverse prognostic significance of concentric remodeling of the left ventricle in hypertensive patients with normal left ventricular mass. J Am Coll Cardiol 1995;25:871-8.
103. Sadler DB, Aurigemma GP, Williams DW, Reda DJ, Materson BJ, Gottdiener JS. Systolic function in hypertensive men with concentric remodeling. Hypertension 1997;30:777-81.
104. Devereux RB, Bella JN, Palmieri V, et al. Left ventricular systolic dysfunction in a biracial sample of hypertensive adults: the Hypertension Genetic Epidemiology Network (HyperGEN) Study. Hypertension 2001;38:417-23.
105. Wachtell K, Rokkedal J, Bella JN, et al. Effect of electrocardiographic left ventricular hypertrophy on left ventricular systolic function in systemic hypertension (the LIFE Study). Am J Cardiol 2001;87:54-60.
106. Vasan RS, Larson MG, Benjamin EJ, Evans JC, Levy D. Left ventricular dilatation and the risk of congestive heart failure in people without myocardial infarction. N Engl J Med 1997;336:1350-5.
107. Drazner MH, Rame JE, Marino EK, et al. Increased left ventricular mass is a risk factor for the development of a depressed left ventricular ejection fraction within five years: the Cardiovascular Health Study. J Am Coll Cardiol 2004;43:2207-15.
108. Drazner MH. The transition from hypertrophy to failure: how certain are we? Circulation 2005;112:936-8.
109. Margulies KB, Matiwala S, Cornejo C, Olsen H, Craven WA, Bednarik D. Mixed messages: transcription patterns in failing and recovering human myocardium. Circ Res 2005;96:592-9.
110. Burkhoff D, Klotz S, Mancini DM. LVAD-induced reverse remodeling: basic and clinical implications for myocardial recovery. J Card Fail 2006;12:227-39.
111. Sides MB, Vernikos J, Convertino VA, et al. The Bellagio Report: cardiovascular risks of spaceflight: implications for the future of space travel. Aviat Space Environ Med 2005;76:877-95.
112. Katz AM. Maladaptive growth in the failing heart: the cardiomyopathy of overload. Cardiovasc Drugs Ther 2002;16:245-9.
113. Opie LH, Commerford PJ, Gersh BJ, Pfeffer MA. Controversies in ventricular remodelling. Lancet 2006;367:356-67.
114. Jessup M, Brozena S. Heart failure. N Engl J Med 2003;348:2007-18.
115. Esposito G, Rapacciuolo A, Naga Prasad SV, et al. Genetic alterations that inhibit in vivo pressure-overload hypertrophy prevent cardiac dysfunction despite increased wall stress. Circulation 2002;105:85-92.
116. Berenji K, Drazner MH, Rothermel BA, Hill JA. Does load-induced ventricular hypertrophy progress to systolic heart failure? Am J Physiol Heart Circ Physiol 2005;289:H8-H16.
117. Takimoto E, Kass DA. Role of oxidative stress in cardiac hypertrophy and remodeling. Hypertension 2007;49:241-8.
118. Moens AL, Kass DA. Tetrahydrobiopterin and cardiovascular disease. Arterioscler Thromb Vasc Biol 2006;26:2439-44.
119. Neubauer S. The failing heart - an engine out of fuel. N Engl J Med 2007;356:1140-51.
120. McMullen JR, Amirahmadi F, Woodcock EA, et al. Protective effects of exercise and phosphoinositide 3-kinase(p110alpha) signaling in dilated and hypertrophic cardiomyopathy. Proc Natl Acad Sci U S A 2007;104:612-7.
121. Fazio S, Palmieri EA, Affuso F, et al. Effects of growth hormone on exercise capacity and cardiopulmonary performance in patients with chronic heart failure. J Clin Endocrinol Metab 2007;92:4218-23.
122. van Rooij E, Sutherland LB, Qi X, Richardson JA, Hill J, Olson EN. Control of stress-dependent cardiac growth and gene expression by a microRNA. Science 2007;316:575-9.
123. Packer M. The impossible task of developing a new treatment for heart failure. J Card Fail 2002;8:193-6.
124. Sussman MA, Anversa P. Myocardial aging and senescence: where have the stem cells gone? Annu Rev Physiol 2004;66:29-48.
125. Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004;350:2140-50.
126. Cleland JG, Daubert JC, Erdmann E, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005;352:1539-49.
127. Rosamond W, Flegal K, Friday G, et al. Heart disease and stroke statistics - 2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2007;115(5):e69-e171.